Phase 3 Clinical Trials With Primary Completion Dates in August 2022

This is a list of Phase 3 trials with primary completion dates in August 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
BVNRY Bavarian Nordic A/S 2022-08-01 Phase 3 NCT02977715 IMVAMUNEĀ® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo
INO Inovio Pharmaceuticals, Inc. 2022-08-01 Phase 3 NCT03721978 REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
KRTX Karuna Therapeutics, Inc. 2022-08-01 Phase 3 NCT04738123 A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
VTGN VistaGen Therapeutics, Inc. 2022-08-01 Phase 3 NCT05011396 PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2